[HTML][HTML] Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow …
Background Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
[引用][C] Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow …
PJ Hayden, C Roddie, P Bader… - Annals of …, 2022 - produccioncientifica.usal.es
Background: Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation …
PJ Hayden, C Roddie, P Bader… - Annals of …, 2022 - epub.uni-regensburg.de
Management of adults and children receiving CAR T-cell therapy: 2021 best practice
recommendations of the European Society for Blood and Marrow Transplantation (EBMT) …
recommendations of the European Society for Blood and Marrow Transplantation (EBMT) …
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation …
PJ Hayden, C Roddie, P Bader, GW Basak… - Annals of …, 2022 - annalsofoncology.org
Background Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation …
PJ Hayden, C Roddie, P Bader, GW Basak… - ANNALS OF …, 2022 - iris.unisr.it
Background: Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation …
PJ Hayden, C Roddie, P Bader… - Annals of …, 2022 - researchinformation.amsterdamumc …
Background: Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation …
PJ Hayden, C Roddie, P Bader… - Annals of oncology …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation …
PJ Hayden, C Roddie, P Bader, GW Basak… - Annals of Oncology …, 2021 - europepmc.org
Background Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
[PDF][PDF] Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow …
PJ Hayden, C Roddie, P Bader, GW Basak, H Bonig… - ppm.wum.edu.pl
Background: Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
Management of Adults and Children receiving CAR T-cell therapy: 2021 Best Practice Recommendations of the European Society for Blood and Marrow …
PJ Hayden, C Roddie, P Bader, GW Basak… - Annals of …, 2021 - discovery.ucl.ac.uk
BACKGROUND: Several commercial and academic autologous chimeric antigen receptor T-
cell products targeting CD19 have been approved in Europe for relapsed/refractory B-cell …
cell products targeting CD19 have been approved in Europe for relapsed/refractory B-cell …